优乐游戏手机版

  • 在线客服

  • 我的麦克林
      账号  
      密码  
             忘记密码 | 免费注册  

  • 我的收藏

  • 我的订单

  • 快速订购

  • 订购/客服:400-623-8666 | 021-50706066
    通过类别精选:
    手性药用中间体
    手性催化剂,配体和试剂
    手性助剂
    手性砌块
    拆分试剂

    COA查询:

    例如:
    批号:C10268951
    货号:A800295-25g

    在货品标签上如何找到货号和批号?
    点击这里查看标签示例
    产品编号 CAS号 项目名称规格 分子式 加入购物车
    85116-37-6
    (-)-B-氯化二异松香芹硼烷, 60% in Heptane, ca. 1.7 mol/L, MkSeal
    (-)-B-Chlorodiisopinocampheylborane, 60% in Heptane, ca. 1.7 mol/L, MkSeal
    C20H34BCl
    1429939-35-4
    (+)-1,13-双[二(3,5-二甲基苯基)膦]-(5AR,8AR,14aR)-5a,6,7,8,8a,9-六氢-5-H-[1]苯并吡喃, 98%purity,99%e.e.
    (R,R,R)-(+)-XYL-SKP, 98%purity,99%e.e.
    C52H54O2P2
    112246-73-8
    (+)二异松蒎基氯硼烷, 60% in Heptane,ca. 1.7mol/L
    (+)-B-Chlorodiisopinocampheylborane, 60% in Heptane,ca. 1.7mol/L
    C20H34BCl
    1439556-82-7
    (-)-1,13-Bis(diphenyl)phosphino-(5aS,8aS,14aS)-5a,6,7,8,8a,9-hexahydro-5H-[1]benzopyrano [3,2-d]xanthene, 98%purity,99%e.e.
    (S,S,S)-(-)-Ph-SKP, 98%purity,99%e.e.
    C44H38O2P2
    1429939-31-0
    (-)-1,13-Bis[di(3,5-dimethylphenyl)phosphino]-(5aS,8aS,14aS)-5a,6,7,8,8a,9-hexahydro-5H-[1]benzopyrano[3,2-d]xanthene, 98%purity,99%e.e.
    (S,S,S)-(-)-Xyl-SKP, 98%purity,99%e.e.
    C52H54O2P2
    1548897-80-8
    (-)-1,13-Bis[di(4-methylphenyl)phosphino]-(5aS,8aS,14aS)-5a,6,7,8,8a,9-hexahydro-5H-[1]benzopyrano[3,2-d]xanthene, 98%purity,99%e.e.
    (S,S,S)-(-)-Tol-SKP, 98%purity,99%e.e.
    C48H46O2P2
    1372719-95-3
    (11aR)-10,11,12,13-Tetrahydro-5-hydroxy-3,7-bis[2,4,6-trisisopropylphenyl]-5-oxide-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin, ≥98%,99%e.e.
    (11aR)-10,11,12,13-Tetrahydro-5-hydroxy-3,7-bis[2,4,6-trisisopropylphenyl]-5-oxide-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin, ≥98%,99%e.e.
    C47H59O4P
    1297613-73-0
    (11aR)-10,11,12,13-Tetrahydro-5-hydroxy-3,7-di-1-naphthalenyl-5-oxide-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin, ≥98%,99%e.e.
    (11aR)-10,11,12,13-Tetrahydro-5-hydroxy-3,7-di-1-naphthalenyl-5-oxide-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin, ≥98%,99%e.e.
    C37H27O4P
    1297613-74-1
    (11aR)-10,11,12,13-Tetrahydro-5-hydroxy-3,7-di-2-naphthalenyl-5-oxide-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin, ≥98%,99%e.e.
    (11aR)-10,11,12,13-Tetrahydro-5-hydroxy-3,7-di-2-naphthalenyl-5-oxide-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin, ≥98%,99%e.e.
    C37H27O4P
    1372719-93-1
    (11aR)-10,11,12,13-Tetrahydro-5-hydroxy-3,7-di-9-phenanthrenyl-5-oxide-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin, ≥98%,99%e.e.
    (11aR)-10,11,12,13-Tetrahydro-5-hydroxy-3,7-di-9-phenanthrenyl-5-oxide-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin, ≥98%,99%e.e.
    C45H31O4P
    1297613-72-9
    (11aR)-10,11,12,13-Tetrahydro-5-hydroxy-3,7-diphenyl-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin, ≥98%,99%e.e.
    (11aR)-10,11,12,13-Tetrahydro-5-hydroxy-3,7-diphenyl-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin, ≥98%,99%e.e.
    C29H23O4P
    930784-57-9
    (11aR)-10,11,12,13-Tetrahydro-N,N,3,7-tetramethyl-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin-5-amine, ≥98%
    (11aR)-10,11,12,13-Tetrahydro-N,N,3,7-tetramethyl-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin-5-amine, ≥98%
    C21H24NO2P
    500997-69-3
    (11aR)-10,11,12,13-Tetrahydro-N,N-bis[(1R)-1-phenylethyl]-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin-5-amine, ≥98%,≥99% e.e.
    (11aR)-10,11,12,13-Tetrahydro-N,N-bis[(1R)-1-phenylethyl]-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin-5-amine, ≥98%,≥99% e.e.
    C33H32NO2P
    (11aR)-3,7-Bis((4-(1,1-dimethylethyl)phenyl)-10,11,12,13-tetrahydro-5-hydroxy-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin, ≥98%,≥99%e.e.
    (11aR)-3,7-Bis((4-(1,1-dimethylethyl)phenyl)-10,11,12,13-tetrahydro-5-hydroxy-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin, ≥98%,≥99%e.e.
    C37H39O4P
    (11aR)-3,7-Bis(1-pyrenyl)-10,11,12,13-tetrahydro-5-hydroxy-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin, ≥95%,≥99%e.e.
    (11aR)-3,7-Bis(1-pyrenyl)-10,11,12,13-tetrahydro-5-hydroxy-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin, ≥95%,≥99%e.e.
    C49H31O4P
    1801196-27-9
    (11aR)-3,7-Bis(2,​4,​6-​trimethylphenyl)-10,11,12,13-tetrahydro-5-hydroxy-5-oxide-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin, ≥98%,99%e.e.
    (11aR)-3,7-Bis(2,​4,​6-​trimethylphenyl)-10,11,12,13-tetrahydro-5-hydroxy-5-oxide-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin, ≥98%,99%e.e.
    C35H35O4P
    (11aR)-3,7-Bis(3,5-dichlorophenyl)-10,11,12,13-tetrahydro-5-hydroxy-5-oxide-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin, ≥98%,≥99%e.e.
    (11aR)-3,7-Bis(3,5-dichlorophenyl)-10,11,12,13-tetrahydro-5-hydroxy-5-oxide-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin, ≥98%,≥99%e.e.
    C29H19Cl4O4P
    1297613-75-2
    (11aR)-3,7-Bis(3,5-dimethylphenyl)-10,11,12,13-tetrahydro-5-hydroxy-5-oxide-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin, ≥98%,99%e.e.
    (11aR)-3,7-Bis(3,5-dimethylphenyl)-10,11,12,13-tetrahydro-5-hydroxy-5-oxide-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin, ≥98%,99%e.e.
    C33H31O4P
    (11aR)-3,7-Bis(4-(trifluoromethyl)phenyl)-10,11,12,13-tetrahydro-5-hydroxy-5-oxide-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin, ≥98%,≥99%e.e.
    (11aR)-3,7-Bis(4-(trifluoromethyl)phenyl)-10,11,12,13-tetrahydro-5-hydroxy-5-oxide-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin, ≥98%,≥99%e.e.
    C31H21F6O4P
    (11aR)-3,7-Bis(4-chlorophenyl)-10,11,12,13-tetrahydro-5-hydroxy-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin, ≥98%,≥99%e.e.
    (11aR)-3,7-Bis(4-chlorophenyl)-10,11,12,13-tetrahydro-5-hydroxy-diindeno[7,1-de:1',7'-fg][1,3,2]dioxaphosphocin, ≥98%,≥99%e.e.
    C29H21Cl2O4P
  • Copyright © 2014 Macklin Inc. - All rights reserved.

    本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或治疗,非药用,非食用。


       
    棋牌游戏手机版棋牌小游戏下载线上棋牌宝利棋牌零点棋牌下载云尚国际棋牌90棋牌